⚗️Anti Estrogens

Selecting the right anti-estrogen depends on whether the user needs an aromatase inhibitor, a selective estrogen receptor modulator, or an androgenic agent with anti-estrogenic properties. Anastrozole, letrozole, and exemestane are aromatase inhibitors that lower circulating estradiol levels. Tamoxifen and clomiphene act as estrogen receptor antagonists in target tissues. Mesterolone is an androgen with anti-estrogenic activity. Athletes typically run these agents to control water retention, gynaecomastia risk, and lipid or hepatic changes associated with high-dose steroid use.

Users report that anastrozole, letrozole, and exemestane effectively reduce estrogen-related side effects such as breast tenderness, water retention, and mood changes when taken at standard doses. Tamoxifen and clomiphene are commonly used to prevent or treat gynaecomastia and support hormonal recovery post-cycle. Mesterolone is often added for its androgenic effects and ability to counteract estrogenic symptoms. Most users note a clear improvement in physical and emotional well-being within days of starting therapy, with full resolution of acute side effects over several weeks.

Common side effects may include headache, dizziness, gastrointestinal discomfort, and rare cases of liver enzyme elevation or hypersensitivity reactions. Anastrozole, letrozole, and exemestane can cause significant suppression of endogenous estrogen if over-dosed, potentially leading to bone density loss and lipid profile abnormalities with prolonged use. Tamoxifen and clomiphene may increase the risk of thromboembolic events at higher doses or in susceptible individuals. Mesterolone is generally well tolerated but can exacerbate androgenic side effects. Blood work, including liver function tests and lipid panels, is recommended for users on extended therapy. Post-cycle protocols should be individualised based on the specific agents used.